Redeye provides its initial take on MedCap’s Q2 2026 report, which came in well above our estimates on both sales and profitability. All three business areas beat our sales forecasts and grew both sequentially and year-on-year, with Specialty Pharma the largest relative beat, while Assistive Tech and MedTech also topped our numbers by a solid margin. Group adjusted EBITA rose 28% y/y to SEK124.5m, comfortably ahead of our estimate. On margins, MedTech’s adjusted EBITA margin jumped to 20.1% (17.4% in Q1 2026), Specialty Pharma to 10.3% (10.1% in Q1 2026) while Assistive Tech’s margin remained strong at 28.1% (28.9% in Q1 2026).
LÄS MER
